Published: 17 May 2019
Author(s): Maria Nikolaou, Christina Chrysohoou, Theodosis Anastasios Georgilas, Gregory Giamouzis, George Giannakoulas, Apostolos Karavidas, Christodoulos Papadopoulos, Sotirios Patsilinakos, Dimitrios Tziakas, John Parissis, for the Hellenic Iron Consensus Group
Issue: May 2019
Section: Review Article

Heart Failure (HF) is a global pandemic with rapidly increasing prevalence. In an attempt to maintain patients well being, the therapeutic interest has expanded to the vicious cycles that confer to HF mortality and morbidity and a number of comorbidities have been targeted. Iron deficiency represents a common comorbid condition that affects outcomes in HF. The treatment of iron deficiency is strongly supported by the cardiologic societies all over the world. Intravenous iron, primarily ferric carboxymaltose, has shown clinical benefit in this setting, irrespective of the anemia status.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.